The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Personalizing ctDNA analysis to predict CRC relapse
Gayathri Anandappa, MBBS, MRCP, MPhil, from The Royal Marsden NHS Foundation Trust, London, UK, describes the ongoing UK multicenter, prospective TRACC study (NCT04050345), which involves minimal residual disease detection through circulating tumor DNA (ctDNA) analysis in stage I-III colorectal cancer (CRC) patients. A retrospective analysis of 122 patients with stage II/III CRC enrolled in this study, which was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, indicates that post-operative plasma ctDNA analysis using tumor-informed multiplex PCR assays could enable the stratification of patient based on risk of recurrence and help guide adjuvant chemotherapy decisions. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
The TRACC study is led by Prof. David Cunningham and supported by Royal Marsden Cancer Charity and NCRI partners. Part C of the TRACC study studying ctDNA guided adjuvant chemotherapy (NIHR 128529) is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership.
